- Home
- ATOS vs ARMP Comparison
ATOS vs ARMP Comparison
Compare ATOS & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- ARMP
- Stock Information
- Founded
- ATOS 2009
- ARMP N/A
- Country
- ATOS United States
- ARMP United States
- Employees
- ATOS N/A
- ARMP N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATOS Health Care
- ARMP Health Care
- Exchange
- ATOS Nasdaq
- ARMP Nasdaq
- Market Cap
- ATOS 107.2M
- ARMP 92.4M
- IPO Year
- ATOS 2012
- ARMP N/A
- Fundamental
- Price
- ATOS $0.84
- ARMP $2.94
- Analyst Decision
- ATOS Strong Buy
- ARMP Strong Buy
- Analyst Count
- ATOS 3
- ARMP 1
- Target Price
- ATOS $6.17
- ARMP $9.00
- AVG Volume (30 Days)
- ATOS 473.0K
- ARMP 12.5K
- Earning Date
- ATOS 11-11-2025
- ARMP 11-12-2025
- Dividend Yield
- ATOS N/A
- ARMP N/A
- EPS Growth
- ATOS N/A
- ARMP N/A
- EPS
- ATOS N/A
- ARMP N/A
- Revenue
- ATOS N/A
- ARMP $6,868,000.00
- Revenue This Year
- ATOS N/A
- ARMP $8.43
- Revenue Next Year
- ATOS N/A
- ARMP N/A
- P/E Ratio
- ATOS N/A
- ARMP N/A
- Revenue Growth
- ATOS N/A
- ARMP 84.67
- 52 Week Low
- ATOS $0.55
- ARMP $0.90
- 52 Week High
- ATOS $1.66
- ARMP $3.14
- Technical
- Relative Strength Index (RSI)
- ATOS 60.84
- ARMP 61.74
- Support Level
- ATOS $0.81
- ARMP $2.79
- Resistance Level
- ATOS $0.80
- ARMP $3.03
- Average True Range (ATR)
- ATOS 0.03
- ARMP 0.15
- MACD
- ATOS 0.01
- ARMP 0.02
- Stochastic Oscillator
- ATOS 92.67
- ARMP 72.97
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.